Buprenorphine and Integrated HIV Care Evaluation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00124358 |
Recruitment Status
: Unknown
Verified March 2007 by The New York Academy of Medicine.
Recruitment status was: Recruiting
First Posted
: July 27, 2005
Last Update Posted
: March 27, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Opioid-Related Disorders HIV Infections AIDS | Drug: Buprenorphine Behavioral: Integrated HIV care and office-based opioid dependence treatment | Phase 4 |
Programs that integrate medical care and drug treatment have shown great promise in improving health and substance use related outcomes. The overlap in the epidemics of HIV (with its complex medical needs) and drug abuse makes HIV-infected drug users a population likely to benefit from the integration of primary care and drug treatment. The Drug Addiction Treatment Act of 2000 and the approval of buprenorphine for the office-based treatment of opioid addiction provide a new opportunity to integrate addiction treatment and medical care for people with HIV. Research has demonstrated the effectiveness of buprenorphine in reducing illicit drug use among opioid dependent people. However, little is known about implementing such programs in HIV care settings, their cost, what effect they have on the health outcomes and substance use behavior of PLWH/A, or their broader impact on providers, institutions, and local systems.
Through this study, approximately 1,350 HIV-infected individuals who meet criteria for opioid dependence will be selected by eleven model demonstration projects located in ten HIV care centers across the U.S. Information on patients’ drug use, HIV health status, service utilization, quality of life, and satisfaction with services as well as information about providers’ practices and attitudes towards treating drug dependent patients will be collected through face-to-face interviews, audio computer-assisted self-interviewing, written surveys, and chart abstractions. These data will be used to help replicate effective programs that integrated HIV care and drug treatment and to improve the care of HIV-infected opioid dependent individuals.
Comparisons: All eleven programs will compare a group of patients who receive integrated buprenorphine treatment and HIV care to a group of patients who receive an alternate intervention. However, the program designs and comparison group interventions vary across the sites and are locally determined. Some sites will implement randomized control designs, while others will use observational methods.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 1350 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings |
Study Start Date : | August 2005 |
Estimated Study Completion Date : | December 2008 |

- Substance use outcomes at 1, 3 and 6 months measured by self-report
- Urine toxicology results at 1, 3, 6, and 12 months
- Retention in and adherence to HIV care at 1, 3, 6, and 12 months
- Quality of life at 1, 3, 6, 9, and 12 months
- HIV-related health outcomes at 1, 3, 6, 9, and 12 months

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-infected
- Clinical diagnosis of opioid dependence
- Fluent in English or Spanish
- 18 years or older
Exclusion Criteria:
- Liver function tests (transaminase only) at five times or higher than normal level;
- Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria for benzodiazepine abuse or dependence within the past 6 months;
- DSM-IV criteria for alcohol dependence within the past 6 months;
- Actively suicidal;
- Psychiatric impairment that impedes ability to consent (dementia, delusional, actively psychotic);
- Methadone dose exceeding levels allowing for safe transition to buprenorphine;
- Pregnant women and women actively trying to become pregnant;
- Clinical judgment of local site principal investigator that patient is inappropriate

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00124358
Contact: Ruth Finkelstein, ScD | 212.822.7266 | rfinkelstein@nyam.org | |
Contact: James E Egan, MPH | 212.822.7347 | jegan@nyam.org |
United States, Arizona | |
El Rio Santa Cruz Neighborhood Health Center | Recruiting |
Tucson, Arizona, United States, 85745 | |
Contact: Jeff Thomas, ACSW 520-629-2888 jefft@elrio.org | |
Principal Investigator: Kevin Carmichael, MD | |
United States, California | |
Organization to Achieve Solutions in Substance Abuse | Recruiting |
Oakland, California, United States, 94612 | |
Contact: Laphyne Barrett, MA 510-834-5442 | |
Principal Investigator: Diana Sylvestre | |
University of California San Francisco | Recruiting |
San Francisco, California, United States, 94110 | |
Contact: Bob Thawley 415-476-9296 ext 311 rthawley@php.ucsf.edu | |
Principal Investigator: Paula Lum, MD, MPH | |
Principal Investigator: Jacqueline Tulsky, MD | |
United States, Connecticut | |
Yale University School of Medicine AIDS Program | Recruiting |
New Haven, Connecticut, United States, 06510 | |
Contact: Declan Barry, PhD 203-781-4650 ext 250 declan.barry@yale.edu | |
Principal Investigator: Frederick Altice, MD | |
Principal Investigator: Lynn Sullivan, MD | |
United States, Florida | |
University of Miami School of Medicine | Recruiting |
Miami, Florida, United States, 33136 | |
Contact: Leslie Thompson, RN, BSN 305-243-3838 lthomps@gate.net | |
Principal Investigator: Margaret Fischl, MD | |
Principal Investigator: Lisa Metsch, PhD | |
United States, Illinois | |
The CORE Center | Recruiting |
Chicago, Illinois, United States, 60612 | |
Contact: Mary Jo Tozzi 312-572-4818 mtozzi@corecenter.org | |
Principal Investigator: Jeffrey Watts, MD | |
Sub-Investigator: David Barker, MD | |
United States, Maryland | |
Johns Hopkins University | Recruiting |
Baltimore, Maryland, United States, 21287 | |
Contact: Greg Lucas, MD, PhD 410-614-0560 glucas@jhmi.edu | |
Principal Investigator: Greg Lucas, MD, PhD | |
Sub-Investigator: Yngveld Olsen, MD | |
Sub-Investigator: William Ruby, DO | |
Sub-Investigator: Jeffrey Hsu, MD | |
Sub-Investigator: Jeanne Keruly, CRNP | |
Sub-Investigator: Richard Moore, MD | |
United States, New York | |
Montefiore Medical Center | Recruiting |
New York, New York, United States, 10467 | |
Contact: Galit Sacajiu, MD gsacajiu@montefiore.org | |
Principal Investigator: Chinazo Cunningham, MD | |
Sub-Investigator: Nancy Sohler, PhD, MPH | |
United States, Oregon | |
Oregon Health & Science University | Recruiting |
Portland, Oregon, United States, 97239 | |
Contact: Catherine Pedersen, MPA 503-494-6770 | |
Principal Investigator: P. Todd Korthuis, MD, MPH | |
Sub-Investigator: Dennis McCarty, PhD | |
United States, Rhode Island | |
The Miriam Hospital | Recruiting |
Providence, Rhode Island, United States, 02903 | |
Contact: Helen Loewenthal, MSW 401-793-4824 hloewenthal@lifespan.org | |
Principal Investigator: Timothy Flanigan, MD | |
Sub-Investigator: Peter Friedman, MD, MPH |
Principal Investigator: | Ruth Finkelstein, ScD | New York Academy of Medicine | |
Principal Investigator: | David Fiellin, MD | Yale University |
ClinicalTrials.gov Identifier: | NCT00124358 History of Changes |
Other Study ID Numbers: |
063005 H97HA03795 |
First Posted: | July 27, 2005 Key Record Dates |
Last Update Posted: | March 27, 2007 |
Last Verified: | March 2007 |
Keywords provided by The New York Academy of Medicine:
Drug Abuse Drug Addiction Drug Dependence Drug Use Disorders Drug Use Disorder Substance Abuse |
Substance Use Disorder Buprenorphine Opiate Addiction Substance-related disorders HIV |
Additional relevant MeSH terms:
HIV Infections Opioid-Related Disorders Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Substance-Related Disorders |
Chemically-Induced Disorders Mental Disorders Analgesics, Opioid Buprenorphine Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Narcotic Antagonists |